A study for people with GI cancers and two studies for people with advanced and early-stage lung cancer hope to develop better treatment options with the help of immunotherapy.
Providence researchers say comprehensive genomic profiling can be pivotal in identifying gene mutations in a patient and tailoring personalized treatment strategies.
SITC 2023 provides a glimpse into scientific advances and breakthroughs in cancer immunotherapy by researchers from around the world.
Providence Cancer Institute lung cancer expert to present a virtual education talk on lung cancer screening, prevention and latest treatments.
Two new studies available at Earle A. Chiles Research Institute, at division of Providence Cancer Institute of Oregon, to evaluate new treatments for triple-negative breast cancer.
Providence Cancer Institute of Oregon, and research director, Earle A. Chiles Research Institute, Walter J. Urba, M.D., Ph.D., receives award for his contributions to science and community.
Providence Cancer Institute celebrates Advanced Practice Providers Week from September 25 to 29 and recognizes their important contributions more than 25 clinics and programs.
Providence Cancer Institute of Oregon announces new division director and deputy director of Hematology and Medical Oncology.
For Gynecologic Cancer Awareness Month, Providence Cancer Institute highlights a clinical trial that evaluates the safety and effectiveness of a new oral treatment for grade 1 endometrial cancer.
In 2021, Dr. Nicole Schmidt was driving around a curve when she saw a car headed straight for her. The crash sent her to a trauma center and started a journey of healing, learning and becoming.
A phase II trial tests FOLFOX or CAPOX versus FOLFIRINOX in patients with locally advanced rectal cancer, and a phase I trial evaluates TBio-4101 in patients with advanced solid tumors.
Final outcomes from a Providence Cancer Institute-sponsored phase Ib trial evaluating pembrolizumab with either weekly paclitaxel or flat-dose capecitabine in treating patients with metastatic TNBC.